Navigation Links
Chemosensitivity/Resistance Assay Included as Part of the NCCN Principles of Chemotherapy
Date:2/25/2010

PITTSBURGH, Feb. 25 /PRNewswire/ -- Precision Therapeutics announced today that The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section. While the NCCN Guidelines™ state that this technology is not intended to supplant standard of care chemotherapy, chemosensitivity/resistance assays are being used in some NCCN Member Institutions for decisions related to future chemotherapy in situations where there are multiple equivalent chemotherapy options available. This is a NCCN category 3 recommendation.

Recent studies presented at ASCO and published in the International Journal of Gynecologic Cancer, evaluated the association between prediction of response to chemotherapy and progression-free interval and overall survival in ovarian cancer.

"We offer our gratitude to NCCN on behalf of the many ovarian cancer patients who could be faced with the potential side effects of ineffective chemotherapies.  Not only are oncologists recognizing the benefits of using chemosensitivity and resistance assays when faced with equivalent therapeutic options, but they are also paving the way for greater support of personalized medicine in oncology," says Karen Kaplan, CEO of the Ovarian Cancer National Alliance.  

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the country's fifth most common cause of cancer mortality in women. In the year 2009, there were more than 21,000 new diagnoses and nearly 15,000 deaths from this neoplasm in the United States.

The NCCN Clinical Practice Guidelines in Oncology™ are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines™ are available free of charge at NCCN.org.

About the Ovarian Cancer National Alliance

The Ovarian Cancer National Alliance is the foremost advocate for women with ovarian cancer in the United States. To advance the interests of women with ovarian cancer, the organization advocates at a national level for increases in research funding for the development of an early detection test, improved health care practices, and life-saving treatment protocols. The Ovarian Cancer National Alliance educates health care professionals and raises public awareness of the signs and symptoms of ovarian cancer.  For more information, visit www.ovariancancer.org.

About Precision Therapeutics

Precision Therapeutics, headquartered in Pittsburgh, Pennsylvania, is a life science company and leader in the development of innovative technology that delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions in cancer therapy.

Precision's ChemoFx®, a proprietary drug response marker, measures an individual patient's tumor response to various chemotherapeutic and biological agents prior to treating the patient. ChemoFx® can complement the physician's experience and provide valuable patient-specific information, particularly when there is non-uniform response to standard cancer treatment or no clear choice for the next regimen.

For more information:

http://www.precisiontherapeutics.com

http://www.chemofx.com

SOURCE Precision Therapeutics

Back to top

RELATED LINKS
http://www.precisiontherapeutics.com

'/>"/>

SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
4. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
5. HERmark(TM) Assay Results in Metastatic Breast Cancer Presented at the San Antonio Breast Cancer Symposium
6. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
7. DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
8. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
9. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
10. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
11. Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  The Global Health Innovative Technology ... formed to battle infectious diseases around the globe, ... that could help deliver a range of new ... This latest round of targeted ... trial testing a pediatric formulation of a drug ...
(Date:3/29/2017)... Calif. , March 29, 2017 ... for patients as the highest standard in quality ... Krypton Vision introduces its objective Wavefront-driven refraction technologies ... subjective approach. This enables an unprecedented level of ... - exceptional vision relegated to Topgun Navy fighter ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and ... Market 2017-2021" report to their offering. ... The global lifestyle drugs market to ... The report, Global Lifestyle Drugs Market 2017-2021, has been ... experts. The report covers the market landscape and its growth prospects ...
Breaking Medicine Technology:
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... A ... suggests that following joint replacement surgery – the best place for a patient to ... when they are in familiar surroundings and have ample opportunity to rest and recover ...
(Date:3/30/2017)... Philadelphia, PA (PRWEB) , ... March 30, 2017 ... ... Wharton School is expanding its educational offerings of corporate finance programs to address ... a new program, will help executives increase their knowledge of sophisticated corporate finance ...
(Date:3/30/2017)... , ... March 30, 2017 , ... An inventor and manicurist from Greet, S.C., wants ... profession I try to help customers maintain clean and healthy feet, so I know the ... of their feet at home, I designed the FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables ...
(Date:3/30/2017)... ... 30, 2017 , ... AudioEducator, a leader in training conferences ... Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, MSN, JD., ... to prevent readmissions in light of the most recent programs at the Centers ...
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week ... free screening colonoscopies to eligible individuals in the local community. , Colon cancer ... regular screenings can detect colon cancer while it is small, confined and easier to ...
Breaking Medicine News(10 mins):